Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1356
Drug: BI 1356/metformin
Drug: Metformin

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02173639

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1356, high dose
Drug: BI 1356, low dose

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02173652

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02171728

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: dabigatran
Drug: Verapamil
Drug: Verapamil ER

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02171533

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Docetaxel
Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02171676

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate generation I
Drug: Dabigatran etexilate generation II

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT02171520

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-BI 10773 - oral solution

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02172274

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium inhalation capsules for oral inhalation

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT02172326

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL i.v.
Drug: BI 1744 CL oral

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11

Registration Number: NCT02172157

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02172131

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy